BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 08/05/2026 pm IST			5-day change	1st Jan Change
317.60 ^SEK	-4.34%		-1.91%	+2.19%

08/05	US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy	MT
08/05	Futures point to negative opening for Stockholm Stock Exchange (update)	FW

Goldman Sachs Raises Price Target for Bioarctic to 367 Kronor (346), Reiterates Buy - BN

Published on 02/19/2026 at 12:14 pm IST

Finwire - Translated by Marketscreener - See original

BIOARCTIC AB

-4.34%

Goldman Sachs raises its price target for Bioarctic to 367 kronor (previously 346), reiterating its buy recommendation - BN

Latest news about BioArctic AB

08/05	US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy	MT
08/05	Futures point to negative opening for Stockholm Stock Exchange (update)	FW
08/05	FDA extends review period for Leqembi Iqlik	FW
29/04	Stockholm edges lower amid earnings deluge, OMXS30 index sheds 0.5 percent	FW
29/04	Volvo Cars and AstraZeneca retreat on earnings, OMXS30 index remains flat	FW
29/04	Leqembi surpasses 500 million euros in annual sales - triggering milestone payment for Bioarctic	FW
29/04	Leqembi sales drive sharp increase in royalties for BioArctic	FW
29/04	Sales generate 161 million SEK in royalties for BioArctic	FW
29/04	BioArctic's Leqembi sales reached 26.2 billion yen in Q1 2026	FW
28/04	BioArctic slides following Goldman Sachs downgrade	FW
28/04	Goldman Sachs downgrades Bioarctic to Neutral (Buy), sets price target at SEK 355 - BN	FW
17/04	BioArctic criticizes recommendation against Leqembi in Sweden	FW
17/04	NT Council advises Swedish regions against using Leqembi for early Alzheimer's treatment (Update)	FW
17/04	NT Council advises Swedish regions against using Leqembi for early Alzheimer's treatment	FW
17/04	Swedish healthcare providers advised against using Bioarctic's Lecanemab	FW

BioArctic AB is a Swedenâ€‘based biopharmaceutical company specializing in the discovery and development of diseaseâ€‘modifying treatments for neurodegenerative disorders. The Companyâ€™s primary focus is on conditions that affect the central nervous system (CNS), including Alzheimerâ€™s disease, Parkinsonâ€™s disease, and amyotrophic lateral sclerosis (ALS), areas characterized by high unmet medical need and limited effective therapies. BioArctic AB conducts advanced research and development of innovative biological drugs, with a particular emphasis on monoclonal antibodies designed to target the underlying disease mechanisms rather than only alleviating symptoms. The Company combines inâ€‘house scientific expertise with strategic collaborations with global pharmaceutical partners to advance and commercialize its therapeutic candidates worldwide.

Employees

129

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q4 2025

More about the company